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Background: Glutaminase 2 (Gls2) is a p53 target gene and is known to play an important role in energy
metabolism. Gls2 has been reported to be downregulated in human hepatocellular carcinomas (HCC). However, the
underlying mechanism responsible for its downregulation is still unclear. Here, we investigated Gls2 expression and
its promoter methylation status in human liver and colon cancers.
Methods: mRNA expression of Gls2 was determined in human liver and colon cancer cell lines and HCC tissues by
real-time PCR and promoter methylation was analyzed by methylation-specific PCR (MSP) and validated by bisulfite
genome sequencing (BGS). Cell growth was determined by colony formation assay and MTS assay. Statistical
analysis was performed by Wilcoxon matched-pairs test or non-parametric t test.
Results: First, we observed reduced Gls2 mRNA level in a selected group of liver and colon cancer cell lines and in
the cancerous tissues from 20 HCC and 5 human colon cancer patients in comparison to their non-cancerous
counter parts. Importantly, the lower level of Gls2 in cancer cells was closely correlated to its promoter
hypermethylation; and chemical demethylation treatment with 5-aza-2′-deoxycytidine (Aza) increased Gls2 mRNA
level in both liver and colon cancer cells, indicating that direct epigenetic silencing suppressed Gls2 expression by
methylation. Next, we further examined this correlation in human HCC tissues, and 60% of primary liver tumor
tissues had higher DNA methylation levels when compared with adjacent non-tumor tissues. Detailed methylation
analysis of 23 CpG sites at a 300-bp promoter region by bisulfite genomic sequencing confirmed its methylation.
Finally, we examined the biological function of Gls2 and found that restoring Gls2 expression in cancer cells
significantly inhibited cancer cell growth and colony formation ability through induction of cell cycle arrest.
Conclusions: We provide evidence showing that epigenetic silencing of Gls2 via promoter hypermethylation is
common in human liver and colon cancers and Gls2 appears to be a functional tumor suppressor involved in the
liver and colon tumorigenesis.
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Hepatocellular carcinoma (HCC) is among the most com-
mon cancers worldwide, especially in Asia, with a high
mortality [1]. It has been well established that hepatitis
virus infection and environmental hepatocarcinogens such
as aflatoxins are the main etiological factors [2,3], while the* Correspondence: dxia@zju.edu.cn
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reproduction in any medium, provided the ormolecular pathogenesis of HCC remains largely unknown.
One important underlying mechanism for HCC develop-
ment is the cumulative genetic and epigenetic alterations.
For instance, the epigenetic changes such as DNA methyla-
tion can lead to the inactivation of tumor suppressor genes
(TSGs) that are known to play important roles in liver car-
cinogenesis [4,5].
DNA methylation occurs mainly at the cytosine bases of
CpG island (CGI) which is found in the promoter region of
genes and plays important roles in controlling gene tran-
scription [6,7]. Once methylated, CGIs can serve as the for-
mation of transcriptional repressive complex whichLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genes [6]. CGIs are generally hypomethylated in normal
cells but frequently hypermethylated in cancer cells [4].
DNA hypermethylation acts as an alternative mechanism
of inactivation of tumor suppressor genes, and it is now
recognized as an important mechanism during tumor initi-
ation and progression [7,8]. In different tumor types, DNA
methylation has been identified in different genes, indicat-
ing unique epigenetic changes. In HCC, DNA methylation
has been described in many tumor suppressor genes, such
as p53, p16INK4a, adenomatous polyposis coli (APC) and
Ras association domain-containing protein 1 (RASSF1a)
[9-11]. Since many tumor suppressor genes are silenced by
DNA methylation, DNA methylation has been proposed as
a marker to identify novel tumor suppressor genes [10-12].
Glutaminase 2 (Gls2) is a mitochondrial glutaminase
catalyzing the hydrolysis of glutamine to glutamate and
it has been identified as a p53 target gene to influence
the energy metabolism [13,14]. Gls2 can regulate anti-
oxidant defense function in cells by decreasing reactive
oxygen species (ROS) levels and protect cells from oxi-
dative stress that is known to contribute to genetic in-
stability and cancer initiation and progression [15,16].
Compared to normal tissue, Gls2 expression is reduced
in liver tumor tissues [13,14]; however, the molecular
mechanism for its downregulation is still not clear.
Since DNA methylation is a common event in the si-
lencing of tumor suppressor genes, we hypothesized thatA
C
Figure 1 Downregulation of Gls2 mRNA level in human liver and colo
and colon (B) cancer cells and normal tissues was determined by real-time
mRNA level in human liver tumor tissues (n = 40), adjacent non-tumor tissu
PCR. The lines denote the mean value. (D) Gls2 mRNA level in human colo
mined by real-time PCR.Gls2 promoter hypermethylation was responsible for its
low expression in cancer cells. Our results revealed that
Gls2 was downregulated in human liver and colon can-
cer cell lines as well as in human liver tumor tissues,
and the lower level of Gls2 was correlated with its pro-
moter hypermethylation. Moreover, overexpression of
Gls2 led to cancer cell growth inhibition and cell cycle
arrest. Our data thus provide useful insights into the
possible role of Gls2 as a functional tumor suppressor
involved in human liver and colon cancers.Methods
Ethics statement
For the human normal and cancerous liver and colon
tissues, written informed consent from the patients was
obtained and this study was reviewed and approved by
the Institutional Ethics Committee of Huashan Hospital
(Shanghai, China).Primary tissues
For 20 HCC and 5 colon cancer patients, the tumor tis-
sues, the adjacent non-tumor tissues and the distant
normal tissues were collected from Huashan Hospital
(Shanghai, China) as frozen samples. The distance be-
tween adjacent non-tumor tissue and tumor tissue
boundary was 2 cm, beyond of which was regarded as
distant normal tissue. The selected tumor areas hadB
D
#1         #2      #3       #4      #5
n cancer cells and HCC tissues. Gls2 mRNA level in human liver (A)
PCR. GAPDH was used to normalize the template amount. (C) Gls2
es (n = 40) and normal tissues (n = 20) was determined by real-time
n tumor tissues and adjacent non-tumor tissues (n = 5) was also deter-
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histology examination.Cell lines
Nine human liver cancer cell lines (HepG2, Hep3B,
Huh7, HCC-LM3, BEL-7402, SMMC-7721, Sk-Hep1,
MHCC-97H and MHCC-97 L) and six human colon
cancer cell lines (HT-29, SW480, SW620, HCT116,
LoVo and WiDr) were all from American Type Cul-
ture Collection (ATCC, Manassas, Va., USA). Unless
specifically indicated, cells were cultured in DMEM
medium (Invitrogen, Carlsbad, CA., USA) supple-
mented with 10% fetal bovine serum at 37°C with 5%
CO2. For pharmacological demethylation, cells were
treated with 5 μM 5-aza-2′-deoxycytidine (Aza)
(Sigma, St. Louis, Mo., USA) for three consecutive
days. Culture medium was changed every 24 hours.Figure 2 Pharmacological genome demethylation upregulated Gls2 e
structure of the Gls2 CpG island (CGI), with the exon 1 and MSP and BGS r
position of MSP and BGS regions was marked with arrows. MSP, methylatio
human liver (B) and colon (C) cancer cells after demethylation treatment w
three independent measurements.An equivalent concentration of vehicle (DMSO) was
used as the control.
RNA/DNA extraction, reverse transcription and real-time
PCR
Total RNA and genomic DNA from both cultured cells
and human tissue samples were extracted using Trizol
reagent (Invitrogen) according to the manufacturer’s in-
structions and their concentrations were quantified by
NanoDrop 1000 (Wilmington, DE., USA). A reverse
transcription reaction was performed using 1 μg of total
RNA with High Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Foster City, CA, USA). The
mRNA level of Gls2 was determined by real-time PCR
using SYBR Green Master Mix Kit and ABI 7500 Real-
Time PCR System (Applied Biosystems, Foster City, CA,
USA). Glyceraldehyde-3- phosphate dehydrogenase
(GAPDH) was used as an internal control. The 2-△△CTxpression in human liver and colon cancer cells. (A) Schematic
egions indicated. Each short vertical line represents one CG site. The
n- specific PCR; BGS, bisulfite genome sequencing. Gls2 expression in
ith 5 μM Aza for three days. Data was presented as mean ± SD from
Figure 3 (See legend on next page.)
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Figure 3 Gls2 promoter region was hypermethylated in human liver and colon cancers. The Gls2 promoter methylation status in cancer
cells was analyzed by MSP (A) and BGS (B-C). For BGS, each circle indicates one CG site and circles filled in black represent methylated CG sites.
One row of circles represents a single colony (B) and a chromatogram representative of BGS results in MHCC-97H and normal liver tissue was also
shown (C). USP, unmethylation-specific PCR; Normal 1, normal liver tissue; Normal 2, normal colon tissue. (D) Gls2 promoter methylation status in
cancer cells after demethylation treatment. (E) The promoter methylation status of Gls2 in 20 pairs of human HCC tissues and adjacent non-
tumor tissues was determined by MSP. (F) Gls2 mRNA level in these tissues was measured by real-time PCR. GAPDH was used to normalize the
template amount. USP, unmethylation-specific PCR. “T” indicates tumor tissues and “N” represents adjacent non-tumor tissues.
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expression from real-time PCR experiments [17]. Real-
time PCR was performed in triplicate. Primers used for
Gls2 were: Gls2-F 5′-TCCAGCTGT -GTTCTGTGGA
G-3′ and Gls2-R 5′-GCAAACTGGCCAGAGAA GTC-
3′ (175 bp product).
Bisulfite treatment of DNA and methylation-specific PCR
Genomic DNA was treated with bisulfite using Zymo
DNA Modification Kit (Zymo Research, Orange, CA,
USA) according to the protocol provided. Methylation
-specific PCR (MSP) was carried out for 40 cycles with
annealing temperature at 60°C. Methylation-specific
primers were: Gls2-MF 5′-GTTGGTCGGTTGTTTTT
GTTC-3′ and Gls2-MR 5′-AAAACTACGAATAA-
TAAAATTATCGTA-3′, and unmethylation -specific
primers were: Gls2-UF 5′-TTTGTAGTTTTATGGTGT
TTTTGG-3′ and Gls2-UR 5′-CCTTACAACAATCTA
CAAATACTTCCAC-3′.
Bisulfite genome sequencing
Bisulfite-treated genomic DNA was amplified using bi-
sulfite genome sequencing (BGS) primers, Gls2-BF: 5′-
GGGTTTATTTTTATTTAGTTTTTTTT-3′ and Gls2-
BR: 5′-AAATAAACAATACCCAAATCCAATC-3′. PCR
products were purified with Illustra GFXTMPCR and gel
band purification kit (GE Healthcare Life Science,
Uppsala, Sweden) and cloned into pCR4-TOPO vector
for sequencing (Invitrogen). At least four colonies were
randomly chosen for plasmid extraction and sequencing
analysis using the ABI PRISM Big Dye Terminator Cycle
Sequencing Kit in the ABI 3100 sequencer (Applied
Biosystems).
Cell growth and colony formation assay
Cells growth was determined by using the MTS assay
(Promega, Madison, WI, USA). Briefly, cells transfected
with either empty vector or 3xFlag-tagged Gls2 express-
ing vector were cultured in a 96-well plate in complete
DMEM for 24 hours. The quantity of formazan was
measured at 490 nm absorbance after one hour incuba-
tion with CellTiter 96A Queous One Solution Reagent
following instructions provided. After overexpression of
Gls2, human liver cancer cell SMMC-7721 and colon
cancer cell HCT116 was used for the colony formationassay. Cells were cultured overnight in a 12-well plate
(5 × 105 cells per well) and transfected with either
empty vector or 3 × Flag-tagged Gls2 expressing vector
[7] (kindly provided by Dr. Tomoaki Tanaka, Chiba
University, Japan) using FuGENE 6 (Roche Applied
Science, Mannheim, Germany). Forty-eight hours later,
the transfectants were replated in 6-well plate and
cultured for 10 ~ 15 days in complete DMEM medium
containing G418 (400 μg/ml). Surviving colonies were
stained with Gentian Violet after methanol fixation and
visible colonies were counted. The experiments were
repeated three times.
Cell cycle analysis
SMMC-7721 and HCT116 cells transfected with either
empty vector or 3 x Flag-tagged Gls2 expressing vector
were trypsinized, washed in PBS and fixed in ice-cold
70% ethanol in PBS. After washing, the fixed cells were
treated with 0.01% RNase (10 mg/ml, Sigma, St. Louis,
MO, USA) for 10 minutes at 37°C and then stained with
0.05% propidium iodide for 20 minutes at 4°C in dark.
The cell cycle distribution was determined using a
FACScanto flow cytometry (Becton Dickinson, Mountain
View, CA, USA) and analyzed with Modfit software
(Phoenix, San Diego, CA, USA).
Western blotting
The transfected cells with either empty vector or
3 x Flag-tagged Gls2 expressing vector were lysed in M2
lysis buffer (20 mM Tris at pH 7, 0.5% NP-40, 250 mM
NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol,
0.5 mM phenylmethylsulfonyl fluoride, 20 mM glycerol
phosphate, 1 mM sodium vanadate and proteinase in-
hibitor cocktail). Equal amount of protein was fraction-
ated on SDS-PAGE and transferred onto PVDF
membrane (Bio-Rad, CA, USA). After blocked with 5%
nonfat milk, the membrane was probed with designated
first and second antibodies (Cell Signaling Technology,
Beverly, MA, USA) and developed with enhanced
chemiluminescence method and visualized by Kodak
Image Station 440CF (Kodak, USA). The band density
was quantified using image processing program and nor-
malized to that of the control group. The first antibodies
used in this study included the following: Phospho-
cdc25c (ser216) from Cell Signaling, #4901, 1:1000
Table 1 Clinical-pathological features of the 20 liver
cancer patients
Characteristics Gls2-methylated Gls2-unmethylated
Age, years 51 ± 10.6 53 ± 12.9
(n) (13) (7)
Gender
M 11 (84.6%) 6 (85.7%)
F 2 (15.4) 1 (14.3%)
HBV infection
Positive 10 (76.9%) 5 (71.4%)
Negative 3 (23.1%) 2 (28.6%)
AFP level
Normal 4 (30.8%) 3 (42.9%)
Abnormal 9 (69.2%) 4 (57.1%)
TNM stage
I-II 3 (23.1%) 2 (28.6%)
III-IV 10 (76.9%) 5 (71.4%)
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#2947, 1:1000 dilution, Cyclin D1 (DCS6) from Cell Sig-
naling, #2926, 1:2000 dilution, and Anti-FLAG® antibody
from Sigma, #F7425, 1:10000 dilution.
Statistical analysis
The numeric data were expressed as mean ± SD. The differ-
ence in Gls2 mRNA levels between paired tissue samples
was determined by the Wilcoxon matched-pairs test. The
difference in Gls2 mRNA levels between two groups was
determined by the non-parametric t test. P < 0.05 was taken
as statistical significance. All the tests were performed by
Graphpad Prism 5.0.
Results
Downregulation of Gls2 in human liver and colon cancer
In this part of our study, we first examined Gls2 mRNA
level in an array of human liver and colon cancer cell lines.
Using real-time PCR, reduced level of Gls2 mRNA was
found in a group of human liver cancer cells (Figure 1A)
and colon cancer cells (Figure 1B) when compared to the
human normal liver and colon tissues, respectively. More
importantly, we found that Gls2 expression was signifi-
cantly downregulated in 85% of human liver tumor tissues
when compared to the adjacent non-tumor tissues and dis-
tant normal tissues (Figure 1C). Similar trend was also ob-
served in colon cancer tissues when we compared the Gls2
mRNA level among 5 pairs of colon tumor tissues vs the
adjacent non-tumor tissues (Figure 1D). Such observations
are generally consistent with the earlier reports that Gls2 is
downregulated in cancers [13,14].
Demethylation treatment increased Gls2 expression in
human liver and colon cancer cells
Using CpG island searcher, two typical CGIs were found
around Gls2 exon 1 using the following criteria: GC
content > 55%, Observed CpG/Expected CpG > 0.65, and
length > 500 bp (Figure 2A), suggesting that DNA
methylation may occur in the promoter region of Gls2.
In order to know whether Gls2 expression is correlated
to DNA methylation, both liver and colon cancer cells
were treated with a demethylation reagent Aza. As
shown in Figure 2B, such a treatment markedly en-
hanced Gls2 mRNA level in almost all the selected hu-
man liver cancer cells. Similar results were also found in
the five human colon cancer cells tested (Figure 2C).
Therefore, such data indicate that the downregulaton of
Gls2 expression in human liver and colon cancer cells is
mediated by its promoter hypermethylation.
Promoter hypermethylation of Gls2 in human liver and
colon cancer cells and HCC tissues
In order to confirm the above findings, we then directly de-
termined the promoter methylation status of Gls2 in bothhuman liver and colon cancer cells by using methylation-
specific PCR (MSP). As shown in Figure 3A, Gls2 promoter
methylation was readily detected in human liver and colon
cancer cells but not in the normal tissues. Bisulfite genomic
sequencing (BGS) also revealed that Gls2 promoter was
heavily methylated in HepG2, MHHC-97H, MHCC-97 L
and HCT116 cells, while it was weakly methylated in hu-
man normal liver and colon tissue (Figure 3B). Representa-
tive chromatograms of MHCC-97H cancer cells and
normal liver tissue were also presented (Figure 3C). More-
over, after demethylation treatment with Aza, lower methy-
lation level of Gls2 was detected in HepG2, Hep3B, HT29
and HCT116 cells, but not in SW480 cells (Figure 3D).
To further confirm the pathological relevance of Gls2
promoter hypermethylation in mediating its downregu-
lation in tumorigenesis, we further analyzed the Gls2
promoter methylation in 20 pairs of human primary
HCC tissues and adjacent non-tumor tissues. As shown
in Figure 3E, higher methylation level of Gls2 was de-
tected in 60% of human liver tumor tissues using MSP.
Importantly, such a pattern is found to be generally con-
sistent with the relative mRNA level of Gls2 measured
in the group of 20 pairs of human primary HCC tissues
and adjacent non-tumor tissues (Figure 3F). In addition,
we also attempted to summarize and compare the
clinical-pathological characteristics of the 20 liver cancer
patients in terms of Gls2 promoter methylation status
(Table 1). It appears that liver cancers with Gls2 pro-
moter methylation were found to have higher percentage
of abnormal AFP and higher TNM stage, although no
statistical differences were found, probably due to the
relative small sample size. Taken together, data from this
part of our study indicate that hypermethylation-
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vant in the tumorigenesis of HCC.
Ectopic expression of Gls2 reduced cancer cell growth
To further investigate the potential tumor suppressive
role of Gls2, human liver cancer cells SMMC-7721 and
human colon cancer cells HCT116 were transfected with
either empty vector or 3 × Flag-tagged Gls2 expressing
vector, and the Gls2 expression in SMMC-7721 and
HCT116 cells was confirmed by western blotting
(Figure 4A). Ectopic expression of Gls2 in both cells
markedly reduced the number of cell colony formed
under the selection of G418 (Figure 4B). When com-
pared to cells transfected with empty vector, overexpres-
sion of Gls2 significantly decreased cell growth rateFigure 4 Gls2 suppressed cancer cell growth and induced cell cycle a
cells. SMMC-7721 and HCT116 cells were transiently transfected with either
pression level of Gls2 was measured by western blot. β-actin served as a lo
mation assay, which was performed as described in Methods. (C) Overexpr
assay. The values obtained from transfected and control cells represent me
groups were calculated using individual Student’s t-test. (D) Changes of th
mined using flow cytometry, with representative histograms shown for eac
(Ser216), p21 and cyclin D1) were determined using western blotting. β-acmeasured by MTS (p < 0.05, Figure 4C). These data sup-
port the tumor suppressive function of Gls2.
To determine the molecular mechanism by which
Gls2 suppressed cancer cell proliferation and colony for-
mation, we further investigated the effect of Gls2 overex-
pression on cell cycle. Gls2 overexpression led to a
significant increase in the number of cells in G2/M
phase in both SMMC-7721 and HCT116 cells (Figure 4D).
To understand the underlying mechanism for Gls2-
mediated G2/M arrest, we examined some of the key cell
cycle regulators changes. Overexpression of Gls2 in cancer
cells induced phosphorylation of the protein phosphatase
cdc25c, a key regulator in the G2/M checkpoint, together
with a significant reduction in p21 and cyclin D1
(Figure 4E).rrest. (A) Ectopic expression of Gls2 in human liver and colon cancer
empty vector or 3 × Flag-tagged Gls2 expressing vector and the ex-
ading control. (B) Cell proliferation ability was measured by colony for-
ession of Gls2 inhibited cancer cell proliferation measured by MTS
an ± SD of three independent experiments. *p < 0.05 between the two
e cell cycle profiles in cancer cells after Gls2 overexpression were deter-
h treatment. (E) Changes of cell cycle regulators (phospho-cdc25
tin was used as the internal control.
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In this study, we first provided the novel evidence link-
ing the lower level of Gls2 with its promoter hyperme-
thylation in both human liver and cancer cells, with the
following observations: (i) Gls2 was downregulated in
human liver and colon cancer cells (Figure 1A and B),
and in primary hepatocellular carcinomas tissues in
comparison to both the distant normal and adjacent
non-tumor tissues (Figure 1C); (ii) demethylation treat-
ment with Aza markedly upregulated Gls2 expression in
human liver and colon cancer cells (Figure 2B and C);
(iii) higher DNA methylation levels were found in hu-
man liver and colon cancer cells and in HCC samples;
and such changes were well correlated to the reduced
Gls2 mRNA level in both cancer cells and cancer tissues
(Figure 3A-F). Moreover, overexpression of Gls2 led to
cell growth inhibition and cell cycle arrest (Figure 4).
Thus, our findings demonstrate that epigenetic silencing
of Gls2 via promoter hypermethylation is an important
event relevant to liver and colon tumorigenesis.
DNA methylation has been well established as an im-
portant molecular mechanism underlying tumorigenesis
[8,11]. Measuring DNA methylation not only serves as a
marker to identify novel TSGs but also can be used as a
sensitive marker for cancer diagnosis and prognosis
[5,18]. In chronic hepatitis C patients, methylation fre-
quencies in many TSGs, such as RASSF1, CDKN2A,
APC, and RUNX3, were associated with shorter time-to-
HCC occurrence [19]. Therefore, epigenetic inactivation
of these genes in chronic hepatitis C patients provides a
prognostic marker for determining the risk for develop-
ing HCC. Besides, poor prognosis of human hepatocellu-
lar carcinoma has been also found to be associated with
epigenetic silencing of some TSGs [20]. Here, we deter-
mined Gls2 methylation status in 20 pairs of primary he-
patocellular carcinomas (Figure 3E-F), suggesting that
Gls2 downregulation is attributed to its promoter hyper-
methylation. It is thus believed that detection of Gls2
promoter methylation in liver tissues could be a useful
biomarker for diagnosis and prognosis of liver cancer.
Although promoter methylation is an important mech-
anism in silencing Gls2 in human liver and colon cancer
cells, we cannot exclude the involvement of other mech-
anisms responsible for Gls2 downregulation, such as his-
tone acetylation [21]. For instance, in Hep3B, HCC-
LM3, SMMC-7721 and SW480 cells, Gls2 expression
failed to be fully upregulated by Aza treatment.
Insteadly, combined treatment with Aza and histone
deacetylase inhibitor TSA could increase Gls2 expres-
sion in these cancer cells (data not shown), suggesting
that histone modification may also mediate Gls2 down-
regulation in cancer cells.
In our study, we found that overexpression of Gls2 mark-
edly suppressed cancer cells proliferation and colonyformation. It has been reported that Gls2 can exert its
tumor suppressive function via reduction of oxidative
stress-induced DNA damage and mutations [15]. However,
other molecular mechanisms responsible for Gls2 as a
tumor suppressor remain unknown. It has been well-
established that cell cycle checkpoints are important con-
trol mechanisms in maintaining tissue homeostasis and one
of the checkpoints, G2/M checkpoint blocks the entry into
mitosis when DNA is damaged [22]. The p53 protein can
regulate G2/M transition either through the induction of
p21 and stratifin, a protein that normally sequesters cyclin
B1-cdc2 complexes in the cytoplasm [23,24], or through
the induction of apoptosis [25,26]. Since Gls2 has been
identified as a p53 target gene, we determined the effect of
Gls2 on cell cycle progression and found that Gls2 overex-
pression induced G2/M phase cell cycle arrest (Figure 4C
and D), indicating its important role in tumor suppression.
In addition to the discussions above, we acknowledge
that there are a number of limitations in this study.
Firstly, due to the relative small samples size, we are un-
able to determine the association of Gls2 promoter
methylation status with the clinical-pathological charac-
teristics (Table 1). Secondly, we did not perform the ana-
lysis of p53 in the human liver cancer tissues and thus
we are unable to link p53 activity with Gls2 expression
level in those patients. And finally, since the adjacent
non-cancerous tissues were not obtained via microdis-
section, technically we could not exclude the presence of
cancerous cells in those specimens, which may explain
the presence of MSP in some of the non-cancerous tis-
sues as shown in Figure 3E.Conclusions
In summary, we found that Gls2 is frequently downregu-
lated in human liver and colon cancer cells and also in
primary HCC tissues, and such downregulation is corre-
lated to its promoter hypermethylation. Moreover, ec-
topic expression of Gls2 suppressed cancer cell growth
through induction of cell cycle arrest. Therefore, it ap-
pears that Gls2 is an important tumor suppressor in-
volved in the liver and colon tumorigenesis. Our results
also suggest that Gls2 is a valuable molecular target for
the detection and treatment of these malignancies.Competing interests
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